Affordable Access

The erythromycin-resistance in S. pyogenes does not limit the human polymorphonuclear cell antimicrobial activity.

Authors
  • Cuffini, A M
  • Tullio, V
  • Banche, G
  • Allizond, V
  • Mandras, N
  • Roana, J
  • Scalas, D
  • Carlone, N A
Type
Published Article
Journal
International Journal of Immunopathology and Pharmacology
Publisher
SAGE Publications
Publication Date
Jan 01, 2009
Volume
22
Issue
1
Pages
239–242
Identifiers
PMID: 19309572
Source
Medline
License
Unknown

Abstract

In order to highlight the potential erythromycin immunomodulatory properties related to different antibiotic resistance patterns in Streptococcus spp., we evaluated the influence of the macrolide on the PMNs primary functions against erythromycin-susceptible (Ery-S) and erythromycin-resistant (Ery-R) S. pyogenes strains. A total of 438 S. pyogenes were isolated over the period 2005-2007. On the basis of the triple disk testing, 345 out of 438 S. pyogenes isolates were Ery-S and 93 were Ery-R; among the resistant strains, 65 displayed the cMLSB phenotype, 23 had the M phenotype and 5 had iMLSB phenotype. Concerning antibacterial activity of PMNs, our results showed that erythromycin did not modify bacterial uptake, but significantly increased the phagocyte intracellular killing, compared with controls, for both Ery-S and Ery-R strains. Consequently, this report underlines that in immunocompetent hosts the dichotomy between the in vitro resistance and clinical trial data for antimicrobial agents should be thoroughly re-evaluated.

Report this publication

Statistics

Seen <100 times